NASDAQ:CHRS - Coherus Biosciences Stock Price, Forecast & News

Coherus Biosciences' stock was trading at $15.87 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CHRS stock has increased by 2.5% and is now trading at $16.26. View which stocks have been mosted impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Coherus Biosciences in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Coherus Biosciences.

Coherus Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Coherus Biosciences.

Coherus Biosciences Inc (NASDAQ:CHRS) issued its quarterly earnings results on Thursday, February, 27th. The biotechnology company reported $0.56 earnings per share for the quarter, missing analysts' consensus estimates of $0.68 by $0.12. The biotechnology company earned $123.86 million during the quarter, compared to analysts' expectations of $123.60 million. Coherus Biosciences had a net margin of 25.23% and a return on equity of 302.63%. View Coherus Biosciences' earnings history.

7 brokerages have issued twelve-month price objectives for Coherus Biosciences' stock. Their forecasts range from $27.00 to $43.00. On average, they expect Coherus Biosciences' stock price to reach $32.86 in the next twelve months. This suggests a possible upside of 102.1% from the stock's current price. View analysts' price targets for Coherus Biosciences.

News stories about CHRS stock have trended very negative recently, InfoTrie reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Coherus Biosciences earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutCoherus Biosciences.

Some companies that are related to Coherus Biosciences include Acceleron Pharma (XLRN), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Iovance Biotherapeutics (IOVA), Ablynx (ABLYF), Momenta Pharmaceuticals (MNTA), Adaptive Biotechnologies (ADPT), Audentes Therapeutics (BOLD), Crispr Therapeutics (CRSP), bluebird bio (BLUE), Allogene Therapeutics (ALLO), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Alector (ALEC) and Fate Therapeutics (FATE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus Biosciences investors own include Chembio Diagnostics (CEMI), Halozyme Therapeutics (HALO), Intelsat (I), Exelixis (EXEL), Bank of America (BAC), Heron Therapeutics (HRTX), Immunomedics (IMMU), Fossil Group (FOSL), Progenics Pharmaceuticals (PGNX) and Sangamo Therapeutics (SGMO).

Coherus Biosciences trades on the NASDAQ under the ticker symbol "CHRS."

Coherus Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Temasek Holdings Private Ltd (10.53%), State Street Corp (4.97%), Lord Abbett & CO. LLC (4.38%), Alliancebernstein L.P. (3.11%), Nuveen Asset Management LLC (2.75%) and UBS Asset Management Americas Inc. (2.73%). Company insiders that own Coherus Biosciences stock include Barbara K Finck, Dennis M Lanfear, James Healy, Jean-Frederic Viret and Vincent R Anicetti. View institutional ownership trends for Coherus Biosciences.

CHRS stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Partner Fund Management L.P., First Trust Advisors LP, Chartwell Investment Partners LLC, Credit Suisse AG, 361 Capital LLC, PNC Financial Services Group Inc., and Russell Investments Group Ltd.. Company insiders that have sold Coherus Biosciences company stock in the last year include Dennis M Lanfear, James Healy, Jean-Frederic Viret, and Vincent R Anicetti. View insider buying and selling activity for Coherus Biosciences.

CHRS stock was purchased by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Temasek Holdings Private Ltd, State Street Corp, Hawk Ridge Capital Management LP, Goldman Sachs Group Inc., UBS Asset Management Americas Inc., Charles Schwab Investment Management Inc., and Panagora Asset Management Inc.. View insider buying and selling activity for Coherus Biosciences.

Shares of CHRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CHRS stock can currently be purchased for approximately $16.26.

Coherus Biosciences has a market capitalization of $1.15 billion and generates $356.07 million in revenue each year. The biotechnology company earns $89.83 million in net income (profit) each year or $1.23 on an earnings per share basis. Coherus Biosciences employs 232 workers across the globe. View additional information about Coherus Biosciences.

The official website for Coherus Biosciences is http://www.coherus.com/.

Coherus Biosciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The biotechnology company can be reached via phone at 650-649-3530 or via email at [email protected]